All the Active Ingredient Drugs
Monoclonal Antibody. Ravulizumab 100 mg/ml. Vial: conc. for sol. for inf. 1X 3 ml/11 ml
The recomm. dosing consists of a loading dose followed by mainten. dosing, by IV infus. The doses are based on the pt’s BW. For adult pts. (≥ 18 years of age), maint. doses should be admin. at a once every 8-week interval, starting 2 weeks after loading dose. See full prescr. info.
For adult and paed. pts with a BW of 10 kg or above with paroxysmal nocturnal haemoglobinuria (PNH): in pts with haemolysis with clin. symptom(s) indicative of high dis. activ. In pts who are clin. stable after having been treated with eculizumab for at least the past 6 months. • tmt. of pts with a body weight of 10 kg or above with atypical haemolytic uremic syndrome( aHUS) who are complement inhib. tmt. naïve or have received eculizumab for at least 3 months and have evidence of resp. to eculizumab. • tmt. of adults with generalized myasthenia gravis (gMG) who are antiacetylcholine receptor (AChR) antibody-pos.• tmt. of adults with neuromyelitis optica spectrum disorder (NMOSD) who are anti-aquaporin 4 (AQP4) antibody-posit.
C/I: Hypersens. /Pts. with unresolved Neisseria meningitidis infect. at tmt. init /Pts. who are not currently vacc. against Neisseria meningitidis unless they receive prophylactic tmt. with appropriate antibiotics until 2 weeks after vaccinat.
